Gilead Sciences shares gain after topping expectations despite lower remdesivir sales

Gilead Sciences (GILD) PT Raised to $112 at Piper Sandler

Piper Sandler analyst Do Kim raised the price target on Gilead Sciences (NASDAQ: GILD) to $112.00 (from $111.00) while maintaining a Overweight rating.... More

After-hours movers: Apple, Amazon, and Google all fall as results disappoint

After-Hours Stock Movers:

Silvergate Capital's (NYSE: SI) 21% LOWER; US prosecutors in the Justice Department's fraud unit are looking into Silvergate Capital's (NYSE: SI) dealing with FTX and Almeda, according to a report from Bloomberg, citing people familiar with the matter.

Ford Motor (NYSE: F) 7% LOWER; reported Q4 EPS of... More

Gilead profit beats Street expectations on COVID and HIV sales

By Michael Erman and Sriparna Roy

(Reuters) -Gilead Sciences Inc on Thursday reported a higher-than-expected fourth-quarter profit driven by strong demand for its HIV and cancer drugs, while COVID-19 antiviral Veklury had sales that were double Wall Street estimates.

The U.S. biotech company also forecast 2023 sales of $26 billion to $26.5 billion, ahead of analyst expectations of $25.8 billion, and adjusted earnings of $6.60 to $7 per share. The midpoint of the earnings forecast is also above analysts' estimates for $6.73 per share.

Gilead Sciences (GILD) Tops Q4 EPS by 17c; Guides

Gilead Sciences (NASDAQ: GILD) reported Q4 EPS of $1.67, $0.17 better than the analyst estimate of $1.50. Revenue for the quarter came in at $7.4 billion versus the consensus estimate of $6.66 billion.

GUIDANCE:

Gilead Sciences sees FY2023 EPS of $6.60-$7.00, versus the consensus of... More